327 related articles for article (PubMed ID: 29304463)
1. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
[TBL] [Abstract][Full Text] [Related]
2. Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.
Tamargo J; Caballero R; Delpón E
Drug Saf; 2022 Feb; 45(2):101-126. PubMed ID: 35025085
[TBL] [Abstract][Full Text] [Related]
3. [Cardiotoxicity of cancer therapy].
Marek J; Linhart A; Rucklová Z; Haber J; Korínek J
Vnitr Lek; 2011 May; 57(5):472-84. PubMed ID: 21695928
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
5. QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics.
Chandrasekhar S; Fradley MG
Curr Treat Options Oncol; 2019 May; 20(7):55. PubMed ID: 31129799
[TBL] [Abstract][Full Text] [Related]
6. Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.
Cuni R; Parrini I; Asteggiano R; Conte MR
Clin Drug Investig; 2017 Feb; 37(2):121-134. PubMed ID: 27638052
[TBL] [Abstract][Full Text] [Related]
7. An update on risk factors for drug-induced arrhythmias.
Vlachos K; Georgopoulos S; Efremidis M; Sideris A; Letsas KP
Expert Rev Clin Pharmacol; 2016; 9(1):117-27. PubMed ID: 26460585
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I
Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110
[TBL] [Abstract][Full Text] [Related]
9. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
10. Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review.
Rao VU; Reeves DJ; Chugh AR; O'Quinn R; Fradley MG; Raghavendra M; Dent S; Barac A; Lenihan D
J Am Coll Cardiol; 2021 Jun; 77(21):2693-2716. PubMed ID: 34045027
[TBL] [Abstract][Full Text] [Related]
11. The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia.
Gatti M; Raschi E; Poluzzi E; Martignani C; Salvagni S; Ardizzoni A; Diemberger I
Curr Heart Fail Rep; 2020 Dec; 17(6):365-383. PubMed ID: 33025463
[TBL] [Abstract][Full Text] [Related]
12. Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs.
Pezo RC; Yan AT; Earle C; Chan KK
Heart; 2019 Nov; 105(21):1649-1655. PubMed ID: 31129611
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract][Full Text] [Related]
14. [Cardiac and vascular toxicity of chemotherapies].
Ederhy S; Ancedy Y; Champiat S; Lopez-Trabada-Ataz D; Dulery R; Cohen A
Rev Prat; 2018 Mar; 68(3):326-329. PubMed ID: 30869300
[TBL] [Abstract][Full Text] [Related]
15. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e93-e104. PubMed ID: 27755247
[TBL] [Abstract][Full Text] [Related]
16. Quality of drug label information on QT interval prolongation.
Warnier MJ; Holtkamp FA; Rutten FH; Hoes AW; de Boer A; Mol PG; De Bruin ML
Int J Risk Saf Med; 2014; 26(2):89-98. PubMed ID: 24902506
[TBL] [Abstract][Full Text] [Related]
17. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of molecular-targeted drug therapy.
Le DL; Cao H; Yang LX
Anticancer Res; 2014 Jul; 34(7):3243-9. PubMed ID: 24982327
[TBL] [Abstract][Full Text] [Related]
19. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer.
Youssef G; Links M
Am J Cardiovasc Drugs; 2005; 5(4):233-43. PubMed ID: 15984906
[TBL] [Abstract][Full Text] [Related]
20. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms.
Alexandre J; Moslehi JJ; Bersell KR; Funck-Brentano C; Roden DM; Salem JE
Pharmacol Ther; 2018 Sep; 189():89-103. PubMed ID: 29698683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
